Ankasa grabs $8.5 mln in first tranche of $17 mln Series A
Biopharmaceutical company Ankasa Regenerative Therapeutics, which focuses on stem cell reactivation, has secured $8.5 million in the first tranche of a $17 million Series A funding round. Avalon Ventures was the lead investor. Heraeus Medical and Correlation Ventures are among the other backers that participated in the round.
23 June 2015•4 mins read
